Time to rethink how we save sight in tiny babies

Article

“It is time for paediatric ophthalmologists to reassess how best to screen and treat their smallest, frailest patients,” said Dr. John Flynn of Columbia University School of Medicine, speaking at the Paediatric Ophthalmology symposium, being held alongside the AAO in San Francisco.

“It is time for paediatric ophthalmologists to reassess how best to screen and treat their smallest, frailest patients,” said Dr. John Flynn of Columbia University School of Medicine, speaking at the Paediatric Ophthalmology symposium, being held alongside the AAO in San Francisco.

Due to astonishing progress in neonatal medicine, younger and smaller babies than ever before are being saved: they often weight less than one pound and may be born 10 to 14 weeks early. Paradoxically, this medical progress has generated new healthcare challenges, including retinopathy of prematurity (ROP), a potentially blinding disease. ROP is more likely to occur in such tiny infants and to be severe and hard to treat successfully even with laser therapy, today's method of choice. Dr Flynn related the history of ROP to today's escalating treatment challenges and the search for new solutions.

From the 1970s onward, paediatric ophthalmologists have been increasingly able to reduce or cure ROP by adapting treatments developed for adult diabetic retinopathy. In the extremely premature infants saved today, though, all treatment parameters are more difficult and vulnerable to failure.

Since 1942, when the use of medically pure oxygen was introduced, doctors have been able to save many more premature babies. But the treatment has also contributed to an epidemic of ROP-related blindness and vision loss in the US and other countries that provide neonatal intensive care. ROP vision loss occurs due to abnormal growth and function of blood vessels that nourish the retina, the light-sensitive area in the back of the eye where images are formed for relay to the brain's visual cortex.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.